JAZZ News and Press, Jazz Pharmaceuticals plc From 10/19/22

Shares of Zymeworks (NYSE: ZYME) were soaring 17% higher as of 10:54 a.m. ET on Wednesday. The big jump came after Zymeworks and Jazz Pharmaceuticals (NASDAQ: JAZZ) announced an exclusive licensing deal for zanidatamab. Jazz will pick up development and marketing rights for ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Zymeworks (NYSE: ZYME ) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ ). This agre...

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) signed a licensing agreement for development and commercialization rights to  Zymeworks' ( NYSE: ZYME ) cancer drug zanidatamab in certain regions. Under the agreement, Jazz will pay $50M upfront, after US antitrust...

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody Canada NewsWire Jazz to obtain exclusive development and commercialization rights in key markets including the ...

Stocks have taken us on a wild ride this year. Every time the market looks to be recovering, it drops again. This back and forth could last for several more weeks or months as we're still dealing with various problems, including geopolitical tensions. It may be discouraging, but having a lo...

The growth in legal marijuana in the United States provides a great long-term opportunity for investors. It is expected to go from a market of just over $35 billion in 2022 to a $61 billion market, with a compound annual growth rate (CAGR) of more than 16%, according to cannabis industry an...

Best Cannabis Stocks For October 2022 Are you trying to find the best marijuana stocks to buy before October ? The whole market experienced large drops following the FOMC meeting. Medical marijuana stocks are one component of the cannabis market whose value has maintained steady. In...

Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022 PR Newswire Seven abstracts emphasize Jazz's leadership in neuroscience and commitment to ongoing innovation DUBLIN , Sept. 15, 2022 /PRNewswire/ -- Jazz Pharmac...

Summary Avadel Pharmaceuticals' LUMRYZ (FT218), with its essential once daily dosing, has snagged a tentative approval from the FDA. Once finally approved, LUMRYZ has serious prospects for knocking off Jazz's flawed blockbuster XYREM/XYWAV duopoly. Tentative approval does not ...

Summary Avadel Pharmaceuticals goes into the spotlight today. This small biopharma company recently got 'tentative' FDA approval for its flagship drug but is still waiting on one patent challenge to move forward to commercialization. How should investors navigate through this ...